Ipsen S.A. Non-GAAP EPS of Euro12.09, revenue of Euro3.68B; sets full-year 2026 guidance and mid-term outlook
Source: SeekingAlpha
2026-02-12 01:25:38 ET
More on Ipsen S.A.
- Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
- Seeking Alpha’s Quant Rating on Ipsen S.A.
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
Read the full article on Seeking Alpha
For further details see:
Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
Ipsen
NASDAQ: IPSEF
IPSEF Trading
100.0% G/L:
$113.13 Last:
5 Volume:
$0 Open:
IPSEF Latest News
March 09, 2026 02:00:00 am
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
February 27, 2026 06:20:11 am
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
